Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300570 · ClinicalTrials.gov registry record · Phase 1
Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03300570: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03300570 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300570, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I trial studies how well dolcanatide works in preventing colorectal cancer in healthy participants. Dolcanatide is similar to a natural hormone released into the intestine. It is thought that people who have low levels of the hormone are more likely to get colon cancer. It may be possible to prevent colon cancer by giving a drug that is similar to the hormone, such as dolcanatide.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- OTHER Placebo Administration
- DRUG Dolcanatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300570
The ClinicalTrials.gov registry entry for NCT03300570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03300570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03300570 about?
NCT03300570 is a clinical study titled "Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers". This phase I trial studies how well dolcanatide works in preventing colorectal cancer in healthy participants. Dolcanatide is similar to a natural hormone released into the intestine. It is thought that people who have low levels of the hormone are more likely to get colon cancer. It may be possible...
What is the current status of trial NCT03300570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-07-27. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT03300570?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Placebo Administration (OTHER), Dolcanatide (DRUG).
Who is sponsoring clinical trial NCT03300570?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.